Miguel Jara Palacios, MD
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1134614464
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,551 of the $4,062 with a category attached, or 87.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,178 and has fallen 79.3% since, to $450 in 2025.
Across 95 payments — averaging $42.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$713
- Abbott$480
- Bayer$478
- Lilly USA, LLC$382
- Boehringer Ingelheim$332
- Dexcom, Inc.$324
- plus $1K from 17 others
What the payments were for
- Grants$571%
- Travel & lodging$45511%
- Food & beverage$3,55187%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 11 | $713 |
| Abbott | 9 | $480 |
| Bayer | 11 | $478 |
| Lilly USA, LLC | 11 | $382 |
| Boehringer Ingelheim | 7 | $332 |
| Dexcom, Inc. | 7 | $324 |
| AstraZeneca | 2 | $262 |
| Insulet Corporation | 4 | $243 |
| Novo Nordisk | 6 | $187 |
| Amryt Pharma Holdings Ltd | 1 | $103 |
| Lexicon Pharmaceuticals, Inc. | 1 | $92 |
| Amgen | 5 | $83 |
| Corcept Therapeutics | 3 | $73 |
| Chiesi USA, Inc. | 3 | $60 |
| Tandem Diabetes Care, Inc. | 3 | $59 |
| BETA Bionics, Inc. | 3 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| OPKO Pharmaceuticals, LLC | 1 | $20 |
| Intra-sana Laboratories | 1 | $15 |
| Cequr Corporation | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$446
- FREESTYLE LIBRE 3$371
- Kerendia$358
- JARDIANCE$347
- DEXCOM G6 TRANSMITTER$157
- Omnipod$156
- Strensiq$135
- MOUNJARO$113
- MYCAPSSA$103
How this compares
$4,062 in reported general payments places this provider in the 55th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 88 | $110,897 |
| OzempicSemaglutide | 66 | $91,924 |
| JardianceEmpagliflozin | 66 | $67,557 |
| TrulicityDulaglutide | 53 | $58,943 |
| RybelsusSemaglutide | 11 | $14,547 |
| FarxigaDapagliflozin Propanediol | 21 | $11,858 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,758 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $6,244 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $1,753 |
| Testosterone | 15 | $1,514 |
| Ezetimibe | 22 | $684 |
| Atorvastatin Calcium | 13 | $346 |
| Pioglitazone Hcl | 21 | $291 |
| Levothyroxine Sodium | 43 | $271 |
| Metformin Hcl ErMetformin Hcl | 18 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $382 | $169,839141 claims |
| Novo NordiskOzempic, Rybelsus | $187 | $106,47177 claims |
| Boehringer IngelheimJardiance | $332 | $67,55766 claims |
| AstraZenecaFarxiga | $262 | $11,85821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Tulsa
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Elie AbedTulsa$10K
- Vishnu Priya PulipatiTulsa$8K
- Maria VargasTulsa$7K
- Christian HansonTulsa$4K
- Deepa PhilipTulsa$4K
- Alekya PolojuTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.